LAB
Standard Biotools Inc
NASDAQ · Life Sciences Tools & Services
$1.26
+0.02 (+1.61%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 189.90M | 172.43M | 380.76M | 337.87M | 394.49M |
| Net Income | -151,211,114 | -123,572,144 | 36.71M | 27.76M | 42.76M |
| EPS | — | — | — | — | — |
| Profit Margin | -79.6% | -75.6% | 9.6% | 8.2% | 10.8% |
| Rev Growth | +10.1% | +10.1% | +8.1% | +3.9% | -1.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 145.3K | 145.3K | 50.74M | 57.07M | 49.88M |
| Total Equity | 242.13M | 242.13M | 238.32M | 239.14M | 240.02M |
| D/E Ratio | 0.00 | 0.00 | 0.21 | 0.24 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -155,325,963 | -133,986,801 | 51.76M | 49.10M | 55.88M |
| Free Cash Flow | — | — | 22.67M | 19.25M | 25.05M |